Gastroenterology
Volume 133, Issue 3 , Pages 818-824 , September 2007

Primary Prophylaxis of Spontaneous Bacterial Peritonitis Delays Hepatorenal Syndrome and Improves Survival in Cirrhosis

  • Javier Fernández

      Affiliations

    • Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain
    • ,
  • Miquel Navasa

      Affiliations

    • Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain
    • Corresponding Author InformationAddress requests for reprints to: Miquel Navasa, MD, Liver Unit, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. fax: (34) 93-4515522.
    • ,
  • Ramón Planas

      Affiliations

    • Gastroenterology Unit, Hospital Germans Trias i Pujol, Barcelona, Spain
    • ,
  • Silvia Montoliu

      Affiliations

    • Gastroenterology Unit, Hospital Germans Trias i Pujol, Barcelona, Spain
    • ,
  • David Monfort

      Affiliations

    • Gastroenterology Unit, Hospital Santa Creu i Sant Pau, Barcelona, Spain
    • ,
  • German Soriano

      Affiliations

    • Gastroenterology Unit, Hospital Santa Creu i Sant Pau, Barcelona, Spain
    • ,
  • Carmen Vila

      Affiliations

    • Gastroenterology Unit, Hospital del Mar, Barcelona, Spain
    • ,
  • Alberto Pardo

      Affiliations

    • Gastroenterology Unit, Hospital Universitario de Canarias, Tenerife, Spain
    • ,
  • Enrique Quintero

      Affiliations

    • Gastroenterology Unit, Hospital Universitario de Canarias, Tenerife, Spain
    • ,
  • Victor Vargas

      Affiliations

    • Gastroenterology Unit, Hospital Vall d’Hebron, Barcelona, Spain
    • ,
  • Jose Such

      Affiliations

    • Gastroenterology Unit, Hospital Universitario, Alicante, Spain
    • ,
  • Pere Ginès

      Affiliations

    • Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain
    • ,
  • Vicente Arroyo

      Affiliations

    • Liver Unit, Hospital Clínic Barcelona, Barcelona, Spain

Received 19 December 2006 ,Accepted 17 May 2007.

  • Image Result

    Probability of developing SBP in patients receiving norfloxacin (dotted line) or placebo prophylaxis (continuous line). Figures in parentheses indicate the cumulative number of subjects who developed

    Probability of developing SBP in patients receiving norfloxacin (dotted line) or placebo prophylaxis (continuous line). Figures in parentheses indicate the cumulative number of subjects who developed SBP.

  • Image Result
    Probability of developing HRS in patients receiving norfloxacin (dotted line) or placebo prophylaxis (continuous line). Figures in parentheses indicate the cumulative number of subjects who developed

    Probability of developing HRS in patients receiving norfloxacin (dotted line) or placebo prophylaxis (continuous line). Figures in parentheses indicate the cumulative number of subjects who developed HRS.

  • Image Result
    Probability of 1-year survival in patients receiving norfloxacin (dotted line) or placebo prophylaxis (continuous line). Figures in parentheses indicate the cumulative number of subjects who died.

    Probability of 1-year survival in patients receiving norfloxacin (dotted line) or placebo prophylaxis (continuous line). Figures in parentheses indicate the cumulative number of subjects who died.

 Supported by grants from the Fondo de Investigación Sanitaria (FIS 00/0921) and the Instituto de Salud Carlos III (BEFI 00/9380 and C03/02).

 ClinicalTrials.gov number: NCT00359853.

PII: S0016-5085(07)01298-X

doi: 10.1053/j.gastro.2007.06.065

Gastroenterology
Volume 133, Issue 3 , Pages 818-824 , September 2007

Article Tools

* Image Usage & Resolution